| Study Name | Description Sort ascending | Trial Category | Trial SubCategory |
|---|---|---|---|
| NRG-GU010 | The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with unfavorable intermediate risk prostate cancer. | Cancer | Prostate |
| EA2183 | The purpose of this study is to determine if adding radiation to chemo is beneficial. You must be diagnosed with metastatic HER2 negative esophageal and gastric cancer. | Cancer | Esophageal |
| NRG-HN005 | The purpose of this study is to determine if a reduced dose of radiation therapy is as effective as the standard dose of radiation. You must be diagnosed with P16-Positive Oropharyngeal cancer. Your smoking history must be <10 pack-years. | Cancer | Oropharyngeal |
| Agendia FLEX | The purpose of this study is to create a large population based database to identify new gene associations in breast cancer. You must be diagnosed with stage 1, 2 or 3 breast cancer. A report is created that looks at the risk of your cancer spreading over the next 10 years. | Cancer | Breast |
| S2200 | The purpose of this study is to compare treatment using cabozantinib with or without atezolizmab. You must be diagnosed with metastatic papillary renal cell cancer. | Cancer | Metastatic Renal Cell |
| Tandem | The purpose of this study is to compare the effects of the study drug, obicetrapib when administered together with the drug ezetimibe as a fixed dose combination. A fixed dose combination means the two drugs are combined into a single tablet. The study will also check how safe obicetrapib and ezetimibe is for participants with high levels of LDL-C in the blood. | Heart & Vascular | Lipid Management; Cardiovascular Disease |
| EA6141 | The purpose of this study is to compare the effectiveness of Nivolumab, Ipilimumab and Sargramostim vs Nivolumab and Ipilmumab. You must be diagnosed with unresectable stage 3 or stage 4 melanoma. | Cancer | Melanoma |
| NRG-LU002 | The purpose of this study is to compare the effectiveness of chemo alone vs SBRT (stereotactic body radiation therapy) and chemo. You must be diagnosed with metastatic non-small cell lung cancer (NSCLC). You must have already received first line therapy. | Cancer | Metastatic Non-Small Cell Lung |
| A031701 | The purpose of this study is to compare standard or dose dense gemcitabine and cisplatin chemo. You must have been diagnosed with muscle invasive bladder cancer. | Cancer | Bladder |
| GU012 | The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. | Cancer | Metastatic Renal Cell |
| EAY191-N4 | The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. | Cancer | Ovarian & Endometrial |
| NRG-GY019 | The purpose of this study is to compare paclitaxel, carboplatin and maintenace letrozole vs letrozole alone. You must be diagnosed with Stage 2-4 serous ovarian cancer. | Cancer | Serous Ovarian |
| A031704 | The purpose of this study is to compare overall survival in patients treated with ipilimumab-nivolumab followed by either nivolumab or cabozantinib-nivolumab. You must be diagnosed with metastatic renal cell cancer. | Cancer | Metastatic Renal Cell |
| A032002 | The purpose of this study is to compare immunotherapy alone vs immunotherapy in combination with radiation for patients with metastatic Urothelial cancer. | Cancer | Metastatic Urothelial |
| A022102 | The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. | Cancer | Esophageal |
| S1925 | The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months. | Cancer | Hematology |
| A081801 (sub study A151216) | The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| S1803 | The purpose of this study is to compare daratumumab and lenalidomide vs lenalidomide alone for maintenance therapy after stem cell transplant. You must be diagnosed with multiple myeloma. | Cancer | Multiple Myeloma |
| E4512 (sub study A151216) | The purpose of this study is to compare Crizotinib vs observation for patients with a ALK+ Fusion Protein to determine if Crizotinib use results in improved disease-free survival. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Lung |
| NRG-LU008 | The purpose of this study is to compare chemo and radiation followed by immunotherapy vs SBRT (stereotactic body radiation therapy) to primary tumor follwed by chemo and radiation then immunotherapy. You must be diagnosed with Stage 2 or 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| S2212 | The purpose of this study is to compare anthracycline-free, taxane-platinum chemo with pembrolizumab to taxane-platinum-anthracycline chemo with pembrolizumab. This study is for people diagnosed with triple negative breast cancer. | Cancer | Breast |
| S2013 | The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy alone not in combination with other treatments. You must have a solid tumor. | Cancer | Solid Tumors |
| TAPUR | The purpose of this study is find targeted treatment for patients with advanced cancer that has a actionable genomic variant revealed by genomic testing. Tissue from your cancer must be sent for genomic screening. You must have an advanced solid tumor, mulitple myeloma or B cell non-Hodgkin lymphona for which standard treatment options are no longer available. | Cancer | All tumor types |
| S1900E (LUNGMAP sub study) | The purpose of this study is determine if the use of Sotorasib is effective in patients with previously treated stage 4 or recuurent KRAS G12C mutated non-squamous non-small cell lung cancer (NSCLC). You must be diagnosed with NSCLC with a KRAS G12C mutation. | Cancer | Metastatic Non-Small Cell Lung |
| EAA173 | The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma. | Cancer | Smoldering Myeloma |
| PFO Occulder (PAS) | The purpose of this research study is to evaluate the commercially available AmplatzerTM PFO Occluder and AmplatzerTM TalismanTM PFO Occluder in preventing another stroke by closing patients patent foramen ovale (PFO). | Heart & Vascular | Structural Heart Disease |
| Librexia AF | The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the brain (non-central nervous system (CNS) systemic embolism) in participants with atrial fibrillation. | Heart & Vascular | Atrial Fibrillation |
| Champion AF | The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. | Heart & Vascular | Atrial Fibrillation |
| Amgen Ocean(a) | The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a). Patients must have a Lp(a) value of ≥ 200 nmol/L during screening. | Heart & Vascular | Cardiovascular Disease |
| Aveir DR | The objective for this study is to confirm the safety and effectiveness of the Aveir LP (Leadless Pacemaker) System in a subject population indicated for a dual chamber pacemaker. | Heart & Vascular | Cardiac Arrhythmia |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.